The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The trial enrolled patients with standard-risk disease who were not undergoing up-front autologous stem-cell transplantation. Following induction treatment with a proteasome inhibitor–lenalidomide combination,
In this video from the 2026 ASCO Annual Meeting, Dr. Mascarenhas, a Professor of Medicine at the Icahn School of Medicine at Mount
Ofirnoflast, a first-in-class, oral, allosteric inhibitor of NEK7, was evaluated in 37 patients and demonstrated clinically meaningful results, according to the investigators, who
The speakers highlighted how combining these powerful drugs into fixed-duration regimens could help patients achieve long-term remissions and move closer to a cure.
The panel also discussed the success of combining teclistamab and daratumumab for functional high-risk patients who historically experience poor outcomes.
The panel also discussed the therapeutic potential of these combinations. Dr. Banerjee highlighted the role of CELMoDs in post-CAR T care, noting that
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974
Dr. Banerjee reviewed the BCMA-sparing clinical efficacy data from the trial and discussed the results, which showed that MeziKd significantly extended progression-free survival
In this interview from the 2026 European Hematology Association Congress, Naseema Gangat, MBBS, a professor of medicine at the Mayo Clinic in Rochester,
The European Commission has granted marketing authorization to epcoritamab (TEPKINLY® ) in combination with rituximab and lenalidomide (R2) for the treatment of relapsed or
